{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_codes_comments in Code Comments (approximate match)
Status:
Investigational
Source:
NCT03481946: Phase 1 Interventional Completed Hemophilia A; Hemophilia B
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00914914: Phase 1 Interventional Completed Refractory Solid Tumors
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02888106: Phase 2 Interventional Completed Chronic Viral Hepatitis B With Delta-agent
(2016)
Source URL:
Class:
PROTEIN
HBVPRES/2-48CONS-MYR (known as Bulevirtide or Myrcludex B) was developed as an agent bind and inactivate the hepatocyte surface protein sodium taurocholate cotransporting polypeptide (SLC10A1 or NTCP). By blocking NTCP, the drug misdirects hepatitis B virus (HBV) and co-infecting hepatitis D virus (HDV) to an unproductive pathway and thereby prevents infection of the cell. Because NTCP is involved in the bile acid transport cycle, the blockade of this target by myrcludex B can potentially be used for the treatment of various metabolic and inflammatory diseases. Myrcludex B is going to participate in phase 3 trial for patients with chronic hepatitis D, however, the study is not yet recruited. The drug successfully completed phase II clinical trial for the patients with chronic hepatitis B and D. In addition, myrcludex B has been studied during preclinical research as a potential treatment of dyslipidemias, non-alcoholic steatohepatitis; primary biliary cirrhosis.
Status:
Investigational
Source:
NCT00001789: Phase 2 Interventional Completed Glomerulonephritis, Membranoproliferative
(1999)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01439971: Phase 1 Interventional Completed Hemophilia A
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exbivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01135108: Phase 2 Interventional Completed Spinal Cord Injury
(2009)
Source URL:
Class:
PROTEIN
KAI 1678 is a first-in-class, isoenzyme selective, a small peptide inhibitor of protein kinase C epsilon. It was in development for the treatment of neuropathic and postoperative pain. However, KAI-1678 treatment results were negative.
Status:
Investigational
Source:
INN:libivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04176133: Phase 2 Interventional Completed Healthy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01392547: Phase 3 Interventional Completed Congenital Bleeding Disorder
(2011)
Source URL:
Class:
PROTEIN
